How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey

Why It Matters

Closing RWD‑identified blind spots can accelerate NSCLC drug development and expand access to targeted treatments, directly impacting patient outcomes and pharma revenue streams.

Key Takeaways

• Biomarker testing gaps leave many NSCLC patients without optimal care
• State laws now mandate insurance coverage for molecular diagnostics
• RWD reveals transportation and SDOH barriers affecting treatment timelines
• Inclusive trials using RWD improve recruitment diversity and drug efficacy

Pulse Analysis

Real‑world data has moved from a niche research tool to a strategic asset for pharmaceutical companies, especially in oncology where patient heterogeneity drives outcomes. In non‑small cell lung cancer, gaps in biomarker testing—often rooted in socioeconomic factors—have historically limited the reach of precision medicines. Recent legislation across multiple states obligates insurers to cover these molecular tests, creating a fertile environment for earlier diagnosis and more precise therapy selection. By capturing data from electronic health records, claims, and patient‑reported outcomes, developers can map the full patient journey, identifying friction points such as limited transportation or delayed test results that traditional clinical trials overlook.

Integrating RWD with social‑determinants‑of‑health (SDOH) insights enables a more nuanced understanding of who participates in trials and why. Researchers can stratify populations based on income, geography, and access to care, allowing them to design enrollment criteria that reflect real‑world diversity. This approach not only improves the external validity of trial results but also accelerates recruitment by targeting underserved cohorts through tailored outreach. Moreover, the enriched data set supports adaptive trial designs, where interventions can be adjusted in near real‑time based on emerging efficacy signals across varied subpopulations.

For the broader industry, the shift toward data‑driven, patient‑centric development promises faster time‑to‑market and stronger market differentiation. Investors are rewarding companies that demonstrate robust RWD capabilities, as these firms can de‑risk pipelines and justify premium pricing for therapies that prove effective across diverse groups. As digital health platforms and interoperable data standards mature, the volume and quality of RWD will only increase, making it a cornerstone of next‑generation drug development strategies. Companies that embed RWD analytics early in the discovery phase will likely capture a competitive edge in the evolving oncology landscape.